Indaptus Therapeutics is trading 5.97% up at $1.00, with no fresh company-specific announcement identified on August 20, 2026.
- Latest notable disclosures were second-quarter results issued August 13 and an August 17 prospectus covering potential resale of 58.895 million shares; neither directly explains today’s gain.
- Biotech is down 2.47%, so the move does not appear sector-driven. Low price and recent volatility suggest momentum trading, but the catalyst remains unclear.